{"id":126685,"date":"2021-08-24T08:22:23","date_gmt":"2021-08-24T15:22:23","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/08\/crispr-pinpoints-new-leukemia-target-and-a-pocket-that-could-make-it-druggable"},"modified":"2021-08-24T08:22:23","modified_gmt":"2021-08-24T15:22:23","slug":"crispr-pinpoints-new-leukemia-target-and-a-pocket-that-could-make-it-druggable","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/08\/crispr-pinpoints-new-leukemia-target-and-a-pocket-that-could-make-it-druggable","title":{"rendered":"CRISPR pinpoints new leukemia target and a \u2018pocket\u2019 that could make it druggable"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/crispr-pinpoints-new-leukemia-target-and-a-pocket-that-could-make-it-druggable.jpg\"><\/a><\/p>\n<p>A team at Penn\u2019s medical school discovered that an epigenetic regulatory protein called ZMYND8 governs the expression of genes that are critical for the growth and survival of AML cells. Inhibiting ZMYND8 in mouse models shrank tumors. The researchers also found a biomarker that they believe could predict which patients are likely to respond to ZMYND8 inhibition, they <a href=\"https:\/\/www.cell.com\/molecular-cell\/fulltext\/S1097-2765(21)00587-6\">reported<\/a> in the journal Molecular Cell.<\/p>\n<p>AML is one of the hardest leukemias to treat, with a five-year survival rate of about 27% in adults. The Penn team had been searching for precision medicine approaches that could improve the prognosis for adults with AML, and they turned to CRISPR for help.<\/p>\n<p>ZMYND8 is known as a \u201chistone reader\u201d in cancer that can recognize epigenetic changes and influence gene expression involved in metastasis.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A team at Penn\u2019s medical school discovered that an epigenetic regulatory protein called ZMYND8 governs the expression of genes that are critical for the growth and survival of AML cells. Inhibiting ZMYND8 in mouse models shrank tumors. The researchers also found a biomarker that they believe could predict which patients are likely to respond to [\u2026]<\/p>\n","protected":false},"author":621,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,412],"tags":[],"class_list":["post-126685","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-genetics"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/126685","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/621"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=126685"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/126685\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=126685"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=126685"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=126685"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}